Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

WW International, formerly known as WeightWatchers, is on track to exit its financial reorganization to cut $1.15 billion in ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer U.S.

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Indian pharmaceutical companies are preparing to flood the market with generic versions of Novo Nordisk’s semaglutide—sold ...

Novo Nordisk, the maker of Ozempic and Wegovy, is predicted to lose billions in profits due to a minor billing error in ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, one method led to much more weight loss.

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...